Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AS-041164 是选择性的,具有口服活性的PI3Kγ亚型抑制剂,IC50=70 nM。它对 PI3Kα (IC50:240 μM),PI3Kβ (IC50:1.45 μM) 和 PI3Kδ (IC50:1.70 μM) 的活性较低。它具有抗炎活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 162 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,270 | 现货 | ||
50 mg | ¥ 2,210 | 现货 | ||
100 mg | ¥ 3,560 | 现货 | ||
200 mg | ¥ 5,150 | 现货 | ||
500 mg | ¥ 7,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | AS-041164 is a selective and orally active PI3Kγ isoform inhibitor(IC50 of 70 nM), and shows less activity against PI3Kα, PI3Kβ, and PI3Kδ (IC50s of 240 nM, 1.45 μM, and 1.70 μM, respectively). It has anti-inflammatory effects. |
靶点活性 | PI3Kγ:70 nM, PI3Kα:240 nM, PI3Kβ:1.4 μM, PI3Kδ:1.7 μM |
体内活性 | AS-041164 (3-100 mg/kg p.o.) treatment dose-dependently decreases r-h regulated on activation normal T cell expressed and secreted (RANTES)-induced neutrophil recruitment in mice.?The ED50 value for AS-041164 is 27.35 mg/kg.?AS-041164 blocks RANTES-induced chemotaxis and reduces the level of AKT phosphorylation.?AS-041164 (10-100 mg/kg; oral administration; once) treatment results in the reduction of inflammatory swelling in the model of carrageenan-induced paw edema. |
分子量 | 249.24 |
分子式 | C11H7NO4S |
CAS No. | 6318-41-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (501.52 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.0122 mL | 20.061 mL | 40.122 mL | 100.3049 mL |
5 mM | 0.8024 mL | 4.0122 mL | 8.0244 mL | 20.061 mL | |
10 mM | 0.4012 mL | 2.0061 mL | 4.0122 mL | 10.0305 mL | |
20 mM | 0.2006 mL | 1.003 mL | 2.0061 mL | 5.0152 mL | |
50 mM | 0.0802 mL | 0.4012 mL | 0.8024 mL | 2.0061 mL | |
100 mM | 0.0401 mL | 0.2006 mL | 0.4012 mL | 1.003 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AS-041164 6318-41-8 PI3K/Akt/mTOR signaling PI3K Inhibitor PI3Kγ inhibit AS041164 Phosphoinositide 3-kinase anti-inflammatory neutrophil recruitment RANTES AS 041164 inhibitor